M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal Pharmaceutical Business ReviewThe proposed offer is set at SFr44.31 per share for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares.Read full story pharminent July 20, 2026 (Last updated: July 23, 2026) Pharmaceutical Business Review The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Read full story Post navigation Previous: FDA Converts Novartis’ Fabhalta to Full Approval in IgA NephropathyNext: Lundbeck preps for key bexicaserin data around year-end Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026